A DOUBLE BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL EVALUATING THE EFFICACY AND SAFETY OF NINTEDANIB OVER 52 WEEKS IN PATIENTS WITH PROGRESSIVE FIBROSING INTERSTITIAL LUNG DISEASE (PF-ILD)
Principal Investigator(s)
Nambiar, Anoop
Funded by
BOEHRINGER INGELHEIM PHARMACEUTICALS
Research Start Date
Status
Active